Home Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation
Article
Licensed
Unlicensed Requires Authentication

Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation

  • Ivica Avbersek-Luznik , Tanja Gmeiner Stopar and Janja Marc
Published/Copyright: August 9, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 8

Abstract

Background: Recently published data identified bone-specific alkaline phosphatase (BALP) as a good marker of bone formation in different bone diseases and osteoporosis. Two methods are available for BALP determination: one measures enzyme activity, the other its mass concentration. We compared results for BALP activity and its mass concentration in a group of 88 healthy pre- and postmenopausal women to identify which is a more useful marker for detecting early menopausal bone remodelling changes.

Methods: We measured BALP activity and BALP mass concentration in relation to femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD) and some other widely used bone markers: osteocalcin (OC), procollagen type I N-terminal propeptide (PINP) and serum C-terminal telopeptide cross-links of type I collagen (CTx) in serum samples from 50 premenopausal (age 45.9±4.6 years) and 38 postmenopausal (age 54.4±4.5 years) women.

Results: Healthy postmenopausal women exhibited 34.2% (p<0.01) and 27.3% (p=0.000) higher levels of BALP activity and mass concentration than premenopausal women, respectively. At the same time, FN and LS BMD were not significantly different between the groups. CTx values were significantly higher in postmenopausal women (p=0.018), while OC and PINP were not. We observed significant correlation between BALP activity and mass concentration (r=0.85, p<0.01). The correlation between BALP activity and FN BMD or LS BMD was insignificant. BALP mass correlated significantly with LS BMD (r=–0.370, p=0.033) but not with FN BMD. As expected, we proved a significant positive correlation for both BALP methods with the other bone markers measured in our study.

Conclusions: Postmenopausal women have slightly higher bone turnover. Since LS and FN BMD were not significantly lower in our group of healthy postmenopausal women, but BALP and CTx were markedly higher, we suggest that measurements of BALP and CTx might be useful as early markers of higher bone turnover. Finally, our results did not show any differences between the clinical utility of BALP activity and BALP mass concentration measurements.

Clin Chem Lab Med 2007;45:1014–8.


Corresponding author: Prof. Janja Marc, Faculty of Pharmacy, Department of Clinical Biochemistry, University of Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia Phone: +386-1-4769500, Fax: +386-1-4258031,

Received: 2007-1-8
Accepted: 2007-4-16
Published Online: 2007-08-09
Published in Print: 2007-08-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Congress of Clinical Chemistry and Laboratory Medicine, Joint Annual Congress of The Austrian Society for Laboratory Medicine and Clinical Chemistry (OEGLMKC) and the The German United Society of Clinical Chemistry and Laboratory Medicine (DGKL), Vienna, Austria, September 19-22, 2007
  2. Interpretation of laboratory results: the Reference Intervals, a necessary evil?
  3. Implementation of haemoglobin A1c results traceable to the IFCC reference system: the way forward
  4. Exhaled breath condensate: a new method for lung disease diagnosis
  5. Biochemical markers of alcoholism
  6. Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy
  7. Association of interleukin-1 genetic polymorphisms with the risk of rheumatoid arthritis in Chinese population
  8. Highest accuracy of combined consensus clinical criteria and SNRPN gene molecular markers in diagnosis of Prader-Willi syndrome in Thai patients
  9. Use of maternal plasma for non-invasive prenatal diagnosis of fetal ABO genotypes
  10. Relationship of the CAG repeat polymorphism of the MEF2A gene and coronary artery disease in a Chinese population
  11. Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification
  12. Increased glycation of hemoglobin and plasma proteins in normotensive, non-diabetic obese Indian subjects: putative role of lipid peroxides
  13. The relationship between red blood cell and reticulocyte indices and serum markers of iron status in the cord blood of newborns
  14. Association of amino-terminal propeptide of type III procollagen and acute myocardial rejection in male patients receiving heart transplantation
  15. Changes in platelet count and indices in pulmonary tuberculosis
  16. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation
  17. A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies
  18. Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples
  19. Partitioning reference values for several subpopulations using cluster analysis
  20. A plea for intra-laboratory reference limits. Part 1. General considerations and concepts for determination
  21. A plea for intra-laboratory reference limits. Part 2. A bimodal retrospective concept for determining reference limits from intra-laboratory databases demonstrated by catalytic activity concentrations of enzymes
  22. Biological variation of thyroid autoantibodies and thyroglobulin
  23. Monitoring glycaemic control: is there evidence for appropriate use of routine measurement of glycated haemoglobin?
  24. Performance and utility of a cost-effective collagen-binding assay for the laboratory diagnosis of Von Willebrand disease
  25. Hook effect in calcitonin immunoradiometric assay
  26. Rapid genotyping of the Ser447Stop variant of the lipoprotein lipase gene using real-time fluorescent PCR
  27. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group
  28. Recommendation for term and measurement unit for “HbA1c”
  29. Desirable performance standards for HbA1c analysis – precision, accuracy and standardisation Consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA)
  30. IFCC Position Paper: Report of the IFCC Taskforce on Ethics: Introduction and framework
  31. IFCC Awards: Call for Nominations
  32. Call for papers, ideas and initiatives
Downloaded on 16.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.186/html
Scroll to top button